Actelion Pharmaceuticals Ltd

Type: Company
Name: Actelion Pharmaceuticals Ltd (Actelion Ltd)
Nationality: Switzerland
Web Address: http://www.actelion.com/
Fact Sheet: Fact Sheet for Actelion Ltd
First reported Jul 28 2014 - Updated 5 hours ago - 3 reports

Pfizer's need for deal looms larger with earnings report

"I definitely think Pfizer will come back for Astra at a somewhat higher bid," Hershkovitz said. But he recommended Pfizer consider smaller targets whose treatments might broaden its existing research priorities, such as Belgium's UCB and Switzerland's ... [Published DailyMe.Com - 5 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Europe shares fall as investors weigh unrest

European Stock Market.| credits: topnews.net.nzEuropean stocks fell for a second day as investors weighed unrest in Ukraine and the Middle East, and watched companies’ financial results.Bloomberg News reported on Monday that Wincor Nixdorf AG slid the ... [Published Nigeria Punch - 8 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Top 100 Agencies 2014: Giant

Share this article:Betting on the value of senior-level talent pays off big for SF agency Giant continues to gain momentum and broaden its scope of work with both new and existing clients. Principal Steven Gold reports revenue at the San Francisco-headquartered ... [Published Medical Marketing And Media - 11 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Earnings Briefs: Biogen, Celgene, Actelion, Cubist

Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro. ... [Published Health News Daily - 12 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Why AMAG Pharmaceuticals (AMAG) Could Be Positioned for a Slump

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security ... [Published Yahoo! Finance - 20 hours ago]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

European Stock-Index Futures Climb After Second Weekly Advance

July 28 (Bloomberg) -- European stock-index futures gained, after the region’s equities climbed for a second week, as investors awaited data on American services and home sales. U.S. index futures were little changed, while Asian shares rose.Ryanair Holdings ... [Published Washington Post - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 3 reports

Actelion Beats on Q2 Earnings and Sales, Revises View

Actelion Ltd. ’s ( ALIOF ) shares gained 2.97% following the company’s second-quarter 2014 earnings results. In the reported quarter, Actelion reported earnings of $2.83 per American Depository Receipt (:ADR), up 203.77% from the prior-year earnings of ... [Published Yahoo! Finance - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 6 reports

Actelion vows to stay independent as profits rise

After posting a healthy set of financials for the first half of the year, and being mentioned by many as a takeover target, Actelion says its portfolio and pipeline mean that independence is the right path.The Swiss drugmaker’s core operating income jumped ... [Published Pharma Times - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

European Stocks Climb After Three-Day Decline as Actelion Rises

European stocks rose, rebounding from three days of losses, as companies reported financial results and the regions foreign ministers met in Brussels to discuss sanctions against Russia. ... [Published Bisnis Indonesia - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

Actelion H1 Profit Rises; Lifts 2014 Guidance - Quick Facts

Actelion Ltd (ALIOF.PK) reported that its first-half pretax profit increased to CHF 336 million from CHF 234 million, last year. Net income was CHF 420 million, compared to CHF 199 million. US-GAAP earnings per share was CHF 3.62, compared to CHF 1.73. ... [Published RTTNews.com - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 4 reports

BRIEF-Actelion rises 4.3 pct after hikes profit forecast

Actelion Ltd :* Shares in Actelion rise 4.3 percent after hikes profitforecast ... [Published Reuters - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

Actelion delivers strong half year operational and financial results

mehr...22.07.2014Actelion: starke operative und finanzielle Ergebnisse im ersten Halbjahr 2014 mehr...15.07.2014Actelion to discuss half year 2014 financial results mehr...16.06.2014Actelion to host Conference Call / Audiocast on the positive GRIPHON ... [Published Quoteline - Jul 22 2014]

Quotes

"I definitely think Pfizer will come back for Astra at a somewhat higher bid" Hershkovitz said...
"Our model has always been to hire strong senior-level people and invest in the right kind of talent,” Gold says. “Just two years ago we were half the size we are now. Last year we saw the investment we made in talent over the past five years really start to pay off in client relationships. We can go head-to-head with anybody and have a great chance of winning.”"
Mark Schoenebaum, the big pharma specialist at ISI, noted over the weekend that Pfizer needs to "explain (again) why you went after AZN and why PFE is OK without it." Not only that, he adds, Pfizer needs to "show us the goods" in the pipeline and see if it can generate some excitement, as well as explain why it shouldn't...
"It's who you have on the inside helping you understand the science" that counts, he said

More Content

All (224) | News (195) | Reports (0) | Blogs (26) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Pfizer's need for deal looms larger with earnin... [Published DailyMe.Com - 5 hours ago]
Europe shares fall as investors weigh unrest [Published Nigeria Punch - 8 hours ago]
Heska (HSKA) Jumps: Stock Adds 5.9% in Session ... [Published Benzinga.com - 10 hours ago]
Top 100 Agencies 2014: Giant [Published Medical Marketing And Media - 11 hours ago]
Earnings Briefs: Biogen, Celgene, Actelion, Cubist [Published Health News Daily - 12 hours ago]
The Pfizer dilemma: Spurned by AstraZeneca, rev... [Published FierceBiotech - 17 hours ago]
Why AMAG Pharmaceuticals (AMAG) Could Be Positi... [Published Yahoo! Finance - 20 hours ago]
European Stock-Index Futures Climb After Second... [Published Washington Post - Jul 28 2014]
Pfizer's need for deal looms larger with earnin... [Published Today Online - Jul 28 2014]
PREVIEW-Pfizer's need for deal looms larger wit... [Published CNBC - Jul 28 2014]
European equities decline as LVMH drags retailers [Published Taipei Times Online - Jul 26 2014]
[Department of Error] Department of Error [Published The Lancet - Jul 25 2014]
Saemor Capital returns 9.3 per cent in first half [Published Hedge Week - Jul 25 2014]
Actelion Q2 net income up [Published Individual.com - Jul 25 2014]
European Stocks Decline as LVMH Leads Luxury Re... [Published Washington Post - Jul 25 2014]
Agenus Inc. (AGEN) Looks Strong as Stock Surges... [Published Yahoo! Finance - Jul 25 2014]
Celsion (CLSN) in Focus: Stock Adds 5.3% in Ses... [Published Yahoo! Finance - Jul 25 2014]
Big Pharma to share abandoned drugs, Actelion M... [Published FierceBiotech - Jul 25 2014]
Actelion Beats on Q2 Earnings and Sales, Revise... [Published Yahoo! Finance - Jul 24 2014]
ACTELION : delivers strong half year operationa... [Published 4 Traders - Jul 24 2014]
Actelion delivers strong half year operational ... [Published Bionity.com - Jul 24 2014]
UPDATE 1-Abuse of U.S. generic-drug rules costs... [Published CNBC - Jul 23 2014]
Macitentan, A New Tool in Pulmonary Arterial Hy... [Published General Medicine eJournal - Jul 23 2014]
Dollar hits a high as global stocks rally [Published Irish Times - Jul 23 2014]
Actelion vows to stay independent as profits rise [Published Pharma Times - Jul 22 2014]
Who's Next Pharma on the Tax Inversion Bullseye? [Published The Big Red Biotech Blog - Jul 22 2014]
Jazz Pharmaceuticals/Concert Pharmaceuticals St... [Published Yahoo! Finance - Jul 22 2014]
Actelion's (ALIOF) CEO Jean-Paul Clozel Discuss... [Published Seeking Alpha - Jul 22 2014]
Swiss Stocks Rally, Led By Resurgent Julius Baer [Published RTTNews.com - Jul 22 2014]
European Stocks Rise As Ukraine Rebels Hand Ove... [Published RTTNews.com - Jul 22 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Department of Error] Department of Error [Published The Lancet - Jul 25 2014]
Devos P, Haeffner-Cavaillon N, Ledoux S, Balandier C, Ménard J. Assessing the French Alzheimer plan. Lancet 2014; 383: 1805—In this Correspondence (May 24), the declaration of interests should have read: “JM was involved in the design of the plan. JM ...
Who's Next Pharma on the Tax Inversion Bullseye? [Published The Big Red Biotech Blog - Jul 22 2014]
According to Bloomberg, that list would include Perrigo Co., in Ireland and Actelion Ltd, in Switzerland. Both would offer US acquirers the chance to redomicile to friendlier tax environs and cut their corporate rates by up to 1/3. It's all the rage you ...
Stocks Desperate To Put Ukraine In Rearview Mir... [Published Zero Hedge - Jul 22 2014]
Following the overnight ramp in various JPY crosses (dragging equity futures higher, and the Nikkei up 0.8%) it is as if the market is desperate to put all of last week's geopolitical events in the rearview mirror, and while yesterday there were no economic ...
The Zacks Analyst Blog Highlights: Anthera Phar... [Published PR Newswire: Financial Services - Jul 21 2014]
CHICAGO, July 21, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently ...
Nosto Solutions picks up $5.5 mln [Published PE Hub Blog - Jul 15 2014]
Finnish e-commerce software firm Nosto Solutions said Tuesday that it has closed $5.5 million in funding. Wellington Partners led the round with participation from Open Ocean Capital, SanomaVentures and Tekes, the Finnish Funding Agency for Innovation ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.